Overexpression of Smad2 and colocalization with TGF-β1 in human pancreatic cancer

Jörg Kleeff, Helmut Friess, Peter Simon, Sergio Susmallian, Peter Büchler, Arthur Zimmermann, Markus W. Büchler, Murray Korc

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Smad2 belongs to a family of cytoplasmic molecules that are critical components in the transforming growth factor β (TGF-β) signaling pathway. Upon ligand binding, the type II TGF-β receptor (TβRII) heterodimerizes with and activates TGF-β receptor type I (TβRI). Activated TβRI phosphorylates Smad2, which then heterodimerizes with Smad4, translocates into the nucleus, and subsequently effects gene transcription. Previously we have shown that pancreatic cancers overexpress TGF-βs and TβRII. Here, we show by northern blot analysis that Smad2 mRNA levels are significantly increased in pancreatic cancer samples in comparison with normal pancreatic tissues. By immunohistochemistry, Smad2 is present in the cancer cells of 67% of the pancreatic cancer samples. Analysis of serial sections reveals coexpression of Smad2 and TGF-β1 in the cancer cells. Furthermore, TGF-β1 increases steady-state levels of Smad2 mRNA in the TGF-β1-sensitive pancreatic cancer cell line COLO-357. It is suggested that pancreatic cancer cells have the capacity to up-regulate Smad2 expression, which may lead to excessive activation of specific components of the TGF-β-signaling pathway.

Original languageEnglish (US)
Pages (from-to)1793-1802
Number of pages10
JournalDigestive diseases and sciences
Volume44
Issue number9
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Transforming Growth Factors
Pancreatic Neoplasms
Growth Factor Receptors
Messenger RNA
Northern Blotting
Neoplasms
Up-Regulation
Immunohistochemistry
Ligands
Cell Line
Genes

Keywords

  • Cancer
  • Pancreas
  • Smad2
  • TGF-β

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Kleeff, J., Friess, H., Simon, P., Susmallian, S., Büchler, P., Zimmermann, A., ... Korc, M. (1999). Overexpression of Smad2 and colocalization with TGF-β1 in human pancreatic cancer. Digestive diseases and sciences, 44(9), 1793-1802. https://doi.org/10.1023/A:1018882320500

Overexpression of Smad2 and colocalization with TGF-β1 in human pancreatic cancer. / Kleeff, Jörg; Friess, Helmut; Simon, Peter; Susmallian, Sergio; Büchler, Peter; Zimmermann, Arthur; Büchler, Markus W.; Korc, Murray.

In: Digestive diseases and sciences, Vol. 44, No. 9, 1999, p. 1793-1802.

Research output: Contribution to journalArticle

Kleeff, J, Friess, H, Simon, P, Susmallian, S, Büchler, P, Zimmermann, A, Büchler, MW & Korc, M 1999, 'Overexpression of Smad2 and colocalization with TGF-β1 in human pancreatic cancer', Digestive diseases and sciences, vol. 44, no. 9, pp. 1793-1802. https://doi.org/10.1023/A:1018882320500
Kleeff, Jörg ; Friess, Helmut ; Simon, Peter ; Susmallian, Sergio ; Büchler, Peter ; Zimmermann, Arthur ; Büchler, Markus W. ; Korc, Murray. / Overexpression of Smad2 and colocalization with TGF-β1 in human pancreatic cancer. In: Digestive diseases and sciences. 1999 ; Vol. 44, No. 9. pp. 1793-1802.
@article{2c631d413d134867a904a408d6a8ca56,
title = "Overexpression of Smad2 and colocalization with TGF-β1 in human pancreatic cancer",
abstract = "Smad2 belongs to a family of cytoplasmic molecules that are critical components in the transforming growth factor β (TGF-β) signaling pathway. Upon ligand binding, the type II TGF-β receptor (TβRII) heterodimerizes with and activates TGF-β receptor type I (TβRI). Activated TβRI phosphorylates Smad2, which then heterodimerizes with Smad4, translocates into the nucleus, and subsequently effects gene transcription. Previously we have shown that pancreatic cancers overexpress TGF-βs and TβRII. Here, we show by northern blot analysis that Smad2 mRNA levels are significantly increased in pancreatic cancer samples in comparison with normal pancreatic tissues. By immunohistochemistry, Smad2 is present in the cancer cells of 67{\%} of the pancreatic cancer samples. Analysis of serial sections reveals coexpression of Smad2 and TGF-β1 in the cancer cells. Furthermore, TGF-β1 increases steady-state levels of Smad2 mRNA in the TGF-β1-sensitive pancreatic cancer cell line COLO-357. It is suggested that pancreatic cancer cells have the capacity to up-regulate Smad2 expression, which may lead to excessive activation of specific components of the TGF-β-signaling pathway.",
keywords = "Cancer, Pancreas, Smad2, TGF-β",
author = "J{\"o}rg Kleeff and Helmut Friess and Peter Simon and Sergio Susmallian and Peter B{\"u}chler and Arthur Zimmermann and B{\"u}chler, {Markus W.} and Murray Korc",
year = "1999",
doi = "10.1023/A:1018882320500",
language = "English (US)",
volume = "44",
pages = "1793--1802",
journal = "Digestive diseases and sciences",
issn = "0163-2116",
number = "9",

}

TY - JOUR

T1 - Overexpression of Smad2 and colocalization with TGF-β1 in human pancreatic cancer

AU - Kleeff, Jörg

AU - Friess, Helmut

AU - Simon, Peter

AU - Susmallian, Sergio

AU - Büchler, Peter

AU - Zimmermann, Arthur

AU - Büchler, Markus W.

AU - Korc, Murray

PY - 1999

Y1 - 1999

N2 - Smad2 belongs to a family of cytoplasmic molecules that are critical components in the transforming growth factor β (TGF-β) signaling pathway. Upon ligand binding, the type II TGF-β receptor (TβRII) heterodimerizes with and activates TGF-β receptor type I (TβRI). Activated TβRI phosphorylates Smad2, which then heterodimerizes with Smad4, translocates into the nucleus, and subsequently effects gene transcription. Previously we have shown that pancreatic cancers overexpress TGF-βs and TβRII. Here, we show by northern blot analysis that Smad2 mRNA levels are significantly increased in pancreatic cancer samples in comparison with normal pancreatic tissues. By immunohistochemistry, Smad2 is present in the cancer cells of 67% of the pancreatic cancer samples. Analysis of serial sections reveals coexpression of Smad2 and TGF-β1 in the cancer cells. Furthermore, TGF-β1 increases steady-state levels of Smad2 mRNA in the TGF-β1-sensitive pancreatic cancer cell line COLO-357. It is suggested that pancreatic cancer cells have the capacity to up-regulate Smad2 expression, which may lead to excessive activation of specific components of the TGF-β-signaling pathway.

AB - Smad2 belongs to a family of cytoplasmic molecules that are critical components in the transforming growth factor β (TGF-β) signaling pathway. Upon ligand binding, the type II TGF-β receptor (TβRII) heterodimerizes with and activates TGF-β receptor type I (TβRI). Activated TβRI phosphorylates Smad2, which then heterodimerizes with Smad4, translocates into the nucleus, and subsequently effects gene transcription. Previously we have shown that pancreatic cancers overexpress TGF-βs and TβRII. Here, we show by northern blot analysis that Smad2 mRNA levels are significantly increased in pancreatic cancer samples in comparison with normal pancreatic tissues. By immunohistochemistry, Smad2 is present in the cancer cells of 67% of the pancreatic cancer samples. Analysis of serial sections reveals coexpression of Smad2 and TGF-β1 in the cancer cells. Furthermore, TGF-β1 increases steady-state levels of Smad2 mRNA in the TGF-β1-sensitive pancreatic cancer cell line COLO-357. It is suggested that pancreatic cancer cells have the capacity to up-regulate Smad2 expression, which may lead to excessive activation of specific components of the TGF-β-signaling pathway.

KW - Cancer

KW - Pancreas

KW - Smad2

KW - TGF-β

UR - http://www.scopus.com/inward/record.url?scp=0032849994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032849994&partnerID=8YFLogxK

U2 - 10.1023/A:1018882320500

DO - 10.1023/A:1018882320500

M3 - Article

VL - 44

SP - 1793

EP - 1802

JO - Digestive diseases and sciences

JF - Digestive diseases and sciences

SN - 0163-2116

IS - 9

ER -